Related Experiment Videos
Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats
1Development Research Laboratories, Banyu Pharmaceutical Co., Ltd. Saitama, Japan.
Abstract:
L-691,121 is a class III antiarrhythmic agent which blocks potassium currents, leading to prolongation of cardiac potential and prevention of cardiac arrhythmia. In a developmental toxicity study in rats, there was a dose-dependent decrease in embryonic/fetal survival, and death of the entire litter was seen at an oral dose of 0.8 mg/kg per day. The critical period for embryolethality was determined as gestational days (GD) 10-13. In a study where females received 1 mg/kg on a critical day (GD 10 or 12) and were killed at 24-h intervals, a high embryonic mortality was seen at 72 h (GD 10 treatment) or 48 h (GD 12 treatment) after dosing. The surviving embryos had morphological abnormalities such as enlarged cardiac tube and pericardium, generalized edema, and hematoma. In order to investigate a possible mechanism for the embryolethality, GD 11 embryos were dissected from females at 4 h after dosing of 1 mg/kg and incubated for 5 h in vitro. The embryonic heart rates were decreased for the first 2 h after incubation but tended to recover to control levels thereafter. When GD 11 embryos were incubated for 4 h with the drug, there were decreases in the heart rates during the entire observation period. In a washout study where the embryos were transferred to drug-free medium after 1-h exposure, decreased heart rates recovered to control levels.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
The antiarrhythmic drug L-691,121 significantly reduced embryonic survival and caused malformations in rats. This drug, which blocks potassium currents, showed a critical period for embryotoxicity between gestational days 10-13.
Area of Science:
- Pharmacology
- Developmental Toxicology
- Cardiology
Background:
- L-691,121 is a class III antiarrhythmic agent.
- It functions by blocking potassium currents, prolonging cardiac potential, and preventing cardiac arrhythmia.
Purpose of the Study:
- To investigate the developmental toxicity of L-691,121 in a rat model.
- To determine the critical period for embryolethality and explore the mechanism of toxicity.
Main Methods:
- Developmental toxicity study in pregnant rats.
- Dose-response assessment for embryonic/fetal survival.
- In vitro incubation of rat embryos with L-691,121 to assess cardiac function.
Main Results:
- A dose-dependent decrease in embryonic/fetal survival was observed.
- Lethal effects occurred at an oral dose of 0.8 mg/kg/day, with a critical period on gestational days 10-13.
- Surviving embryos exhibited morphological abnormalities, and in vitro studies showed drug-induced decreases in embryonic heart rates.
Conclusions:
- L-691,121 exhibits significant embryolethality and teratogenicity in rats.
- The drug's mechanism may involve direct effects on embryonic cardiac function.
- Caution is advised regarding L-691,121 use during pregnancy due to developmental risks.